阅读说明：本技术 一种锡-中卟啉与青蒿素联合应用在制备抗肿瘤药物中的用途 (Application of tin-mesoporphyrin and artemisinin in preparation of antitumor drugs in combined manner ) 是由 苏畅 曹奕鸥 肖立俊 张淳 于 2020-06-09 设计创作，主要内容包括：本发明公开了一种锡-中卟啉与青蒿素联合应用在制备抗肿瘤药物中的用途。所述锡-中卟啉明显抑制血红素加氧酶-1的表达,增加青蒿素对肿瘤细胞的诱导凋亡作用。本发明利用锡-中卟啉抑制肿瘤细胞血红素加氧酶-1活性的作用,减少了肿瘤细胞内亚铁血红素的代谢,提升了青蒿素对肿瘤细胞的诱导凋亡作用,提高青蒿素的抗肿瘤效果。本发明将锡-中卟啉与青蒿素联合应用抗肿瘤效果非常显著,具有广阔的应用前景。(The invention discloses an application of tin-mesoporphyrin and artemisinin in preparation of antitumor drugs in a combined manner. The tin-mesoporphyrin obviously inhibits the expression of heme oxygenase-1 and increases the apoptosis induction effect of artemisinin on tumor cells. The invention utilizes the effect of tin-mesoporphyrin on inhibiting the activity of heme oxygenase-1 of tumor cells, reduces the metabolism of heme in the tumor cells, improves the apoptosis induction effect of artemisinin on the tumor cells, and improves the anti-tumor effect of artemisinin. The invention has very obvious anti-tumor effect by combining tin-mesoporphyrin and artemisinin and has wide application prospect.)

1. An application of tin-mesoporphyrin and artemisinin in preparing antineoplastic medicines is disclosed.

2. The use of a tin-mesoporphyrin in combination with artemisinin for the preparation of an antitumor medicament according to claim 1, wherein: the tin-mesoporphyrin obviously inhibits the expression of heme oxygenase-1 and increases the apoptosis induction effect of artemisinin on tumor cells.

3. A pharmaceutical composition characterized by: including tin-mesoporphyrin and artemisinin.

4. A pharmaceutical composition according to claim 3, wherein: the pharmaceutical composition obviously inhibits the expression of heme oxygenase-1 and increases the apoptosis induction effect of artemisinin on tumor cells.

Technical Field

The invention belongs to the field of antitumor drugs, and particularly relates to an application of tin-mesoporphyrin and artemisinin in preparation of an antitumor drug.

Background

The artemisinin and the derivatives thereof have good effects of inhibiting the proliferation of tumor cells of lung cancer, prostatic cancer, cervical cancer and the like and promoting the apoptosis of the tumor cells, have extremely low toxicity to normal tissue cells, and have good application prospect in the aspect of anticancer treatment. However, artemisinin drugs do not inhibit all types of tumor cells well, and even the sensitivity of artemisinin varies widely between different cell lines of tumors at the same site. The direct target of the antitumor effect of the artemisinin is intracellular heme, the intracellular heme can mediate the cytotoxicity of the artemisinin, the increase of a precursor substance for the synthesis of the heme can enhance the effect of the artemisinin, and the acceleration of the metabolism of the intracellular heme also obviously weakens the cytotoxic effect of the artemisinin. Heme oxygenase-1 is an antioxidant defense enzyme widely present in mammals and is an important rate-limiting enzyme for degrading heme. The expression level of heme oxygenase-1 is increased in a plurality of tumor tissues (gastric cancer, lung cancer, breast cancer, rectal cancer and the like) and is abnormally high expressed. The high expression of heme oxygenase-1 accelerates the metabolism of heme in tumor cells, and inhibits the anticancer effect of artemisinin. The tin-mesoporphyrin has a structure similar to heme, can be combined with heme oxygenase-1, but is not degraded per se, so that the combination of heme oxygenase-1 and heme can be reduced, and the tin-mesoporphyrin can inhibit the activity of heme oxygenase-1, and is clinically used for treating hyperbilirubinemia, hematoporphyria and infantile glucose-6-phosphate dehydrogenase deficiency of newborns.

Disclosure of Invention

The invention aims to solve the technical problems and provides the application of the combination of tin-mesoporphyrin and artemisinin in preparing the antitumor drugs.

The invention is realized by the following technical scheme:

an application of tin-mesoporphyrin and artemisinin in preparing antineoplastic medicines is disclosed.

Furthermore, the tin-mesoporphyrin obviously inhibits the expression of heme oxygenase-1 and increases the apoptosis induction effect of artemisinin on tumor cells.

A pharmaceutical composition comprises tin-mesoporphyrin and artemisinin.

Furthermore, the pharmaceutical composition obviously inhibits the expression of heme oxygenase-1 and increases the apoptosis induction effect of artemisinin on tumor cells.

The invention has the beneficial effects that:

the invention utilizes the effect of tin-mesoporphyrin on inhibiting the activity of heme oxygenase-1 of tumor cells, reduces the metabolism of heme in the tumor cells, improves the apoptosis induction effect of artemisinin on the tumor cells, and improves the anti-tumor effect of artemisinin.

Drawings

FIG. 1 is a graph comparing the heme content of tumor cells with that of normal tissues, which highly express heme oxygenase-1, according to the present invention;

FIG. 2 is a graph showing the results of tin-mesoporphyrin of the present invention significantly inhibiting heme oxygenase-1 expression and increasing artemisinin induced apoptosis in tumor cells;

FIG. 3 is a schematic diagram of the action of tin-mesoporphyrin according to the present invention.

Detailed Description

In order to make the technical solutions of the present invention better understood by those skilled in the art, the technical solutions of the present invention are further described below by way of specific embodiments with reference to the drawings of the specification.